

APPENDIX II

Pending Claims 34-40 with proposed amendments to claims 34, 36, 37 and 39.

34. (amended) A method of producing a prodrug complex for administration to an organism comprising:

(a) identifying a drug;

(b) selecting a synthetic receptor that specifically binds the drug via a saturable, noncovalent interaction between the drug and the synthetic receptor that can be competitively inhibited by structural analogs of the drug, said synthetic receptor being selected from the group consisting of antibodies, antibody fragments, oligonucleotides and oligosaccharides; and

(c) specifically binding the identified drug to the selected synthetic receptor to form a prodrug complex consisting essentially of the identified drug specifically bound to the selected synthetic receptor.

35. The method of claim 34 further comprising attaching the prodrug complex to a biologic or biocompatible structure.

36. (amended) A method of producing a multi-prodrug complex for administration to an organism, said multi-prodrug complex comprising first and second prodrug complexes, wherein the first

prodrug complex is produced in accordance with the method of claim 34 and the second prodrug complex comprises a drug bound to a synthetic receptor.

37. (amended) A prodrug complex for administration to an organism, said prodrug complex being produced in accordance with the method of claim 34.

38. A drug delivery system comprising the prodrug complex of claim 37 attached to a biologic or biocompatible structure selected from the group consisting of molecules, molecular complexes, microstructures, cells, vesicles, microparticles, polymers, gels, matrices, blood forming elements, reticuloendothelial cells, liposomes, microspheres, nanostructures, biopolymers, multimolecular complexes, cell membranes, implants and prosthetic devices.

39. A multi-prodrug complex for administration to an organism, said multi-prodrug complex comprising first and second prodrug complexes, wherein the first prodrug complex is produced in accordance with the method of claim 34 and the second prodrug complex comprises a drug bound to a synthetic receptor.

40. A drug delivery system comprising the multi-prodrug complex of claim 39 attached to a biologic or biocompatible structure selected from the group consisting of molecules, molecular complexes, microstructures, cells, vesicles, microparticles, polymers, gels, matrices, blood forming elements, reticuloendothelial cells, liposomes, microspheres, nanostructures, biopolymers, multimolecular complexes, cell membranes, implants and prosthetic devices.

APPENDIX I

Rejected Claims on Appeal

34. A method of producing and administering a prodrug complex comprising:

- (a) identifying a drug;
- (b) selecting a synthetic receptor that specifically binds the drug via a saturable, noncovalent interaction between the drug and the synthetic receptor that can be competitively inhibited by structural analogs of the drug, said synthetic receptor being selected from the group consisting of antibodies, antibody fragments, oligonucleotides and oligosaccharides;
- (c) specifically binding the identified drug to the selected synthetic receptor to form a prodrug complex; and
- (d) administering the prodrug complex to an organism.

35. The method of claim 35 further comprising attaching the prodrug complex to a biologic or biocompatible structure.

36. A method of producing a multi-prodrug complex for administration to an organism, said multi-prodrug complex comprising at least two prodrug complexes, wherein at least one of the prodrug complexes is produced and administered in accordance with the method of claim 30, 32 or 34.

37. A prodrug complex for administration to an organism, said prodrug complex comprising a drug specifically bound to a synthetic

receptor and being produced and administered in accordance with the method of claim 30, 32 or 34.

38. A drug delivery device system comprising the prodrug complex of claim 37 attached to a biologic or biocompatible structure selected from the group consisting of molecules, molecular complexes, microstructures, cells, vesicles, microparticles, polymers, gels, matrices, blood forming elements, reticuloendothelial cells, liposomes, microspheres, nanostructures, biopolymers, multimolecular complexes, cell membranes, implants and prosthetic devices.

39. A multi-prodrug complex for administration to an organism, said multi-prodrug complex comprising at least two prodrug complexes, wherein at least one of the prodrug complexes is produced and administered in accordance with the method of claim 30, 32 or 34.

40. A drug delivery device system comprising the prodrug complex of claim 39 attached to a biologic or biocompatible structure selected from the group consisting of molecules, molecular complexes, microstructures, cells, vesicles, microparticles, polymers, gels, matrices, blood forming elements, reticuloendothelial cells, liposomes, microspheres, nanostructures, biopolymers, multimolecular complexes, cell membranes, implants and prosthetic devices.